Arnold J Levine

List of Publications by Year
in descending order

40 papers	12,306 citations	218677 26 h-index	276875 41 g-index
42 all docs	42 docs citations	42 times ranked	17212 citing authors

#	Article	IF	Citations
1	Surfing the p53 network. Nature, 2000, 408, 307-310.	27.8	6,352
2	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602.	28.9	1,158
3	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	27.8	854
4	The genetics of the p53 pathway, apoptosis and cancer therapy. Nature Reviews Drug Discovery, 2008, 7, 979-987.	46.4	568
5	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	27.8	532
6	p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer, 2020, 20, 471-480.	28.4	421
7	Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death and Differentiation, 2018, 25, 154-160.	11.2	393
8	A plausible model for the digital response of p53 to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14266-14271.	7.1	319
9	Allele-Specific p53 Mutant Reactivation. Cancer Cell, 2012, 21, 614-625.	16.8	281
10	The Origins and Evolution of the p53 Family of Genes. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001198-a001198.	5.5	239
11	The Roles of Initiating Truncal Mutations in Human Cancers: The Order of Mutations and Tumor Cell Type Matters. Cancer Cell, 2019, 35, 10-15.	16.8	114
12	A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development. Cancer Cell, 2010, 18, 220-230.	16.8	108
13	TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1Î± degradation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 226-231.	7.1	91
14	Winter Temperature and UV Are Tightly Linked to Genetic Changes in the p53 Tumor Suppressor Pathway in Eastern Asia. American Journal of Human Genetics, 2009, 84, 534-541.	6.2	83
15	Multiple Roles of p53-Related Pathways in Somatic Cell Reprogramming and Stem Cell Differentiation. Cancer Research, 2012, 72, 5635-5645.	0.9	78
16	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15154-15159.	7.1	69
17	The evolution of thymic lymphomas in p53 knockout mice. Genes and Development, 2014, 28, 2613-2620.	5.9	64
18	P53 and the defenses against genome instability caused by transposons and repetitive elements. BioEssays, 2016, 38, 508-513.	2.5	60

#	Article	IF	Citations
19	A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2. Journal of Biological Chemistry, 2001, 276, 3785-3790.	3.4	47
20	Topological Data Analysis Generates High-Resolution, Genome-wide Maps of Human Recombination. Cell Systems, 2016, 3, 83-94.	6.2	45
21	The interplay between epigenetic changes and the p53 protein in stem cells. Genes and Development, 2017, 31, 1195-1201.	5.9	40
22	Inference of Ancestral Recombination Graphs through Topological Data Analysis. PLoS Computational Biology, 2016, 12, e1005071.	3.2	38
23	Identification of relevant genetic alterations in cancer using topological data analysis. Nature Communications, 2020, 11, 3808.	12.8	38
24	Lysine methylation represses p53 activity in teratocarcinoma cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9822-9827.	7.1	36
25	The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026153.	6.2	35
26	Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Liâ€"Fraumeni cancer predisposition syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15497-15501.	7.1	29
27	Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget, 2014, 5, 8924-8936.	1.8	29
28	Spontaneous and inherited TP53 genetic alterations. Oncogene, 2021, 40, 5975-5983.	5.9	28
29	A tumor-specific endogenous repetitive element is induced by herpesviruses. Nature Communications, 2019, 10, 90.	12.8	25
30	Fundamental immuneâ€"oncogenicity trade-offs define driver mutationÂfitness. Nature, 2022, 606, 172-179.	27.8	23
31	Targeting the P53 Protein for Cancer Therapies: The Translational Impact of P53 Research. Cancer Research, 2022, 82, 362-364.	0.9	22
32	Dynamic changes during the treatment of pancreatic cancer. Oncotarget, 2018, 9, 14764-14790.	1.8	21
33	The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death and Differentiation, 2022, 29, 938-945.	11.2	18
34	The Evolution of Tumors in Mice and Humans with Germline p53 Mutations. Cold Spring Harbor Symposia on Quantitative Biology, 2015, 80, 139-145.	1.1	17
35	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. Npj Genomic Medicine, 2021, 6, 99.	3.8	13
36	Exploring the future of research in the Tp53 field. Cell Death and Differentiation, 2022, 29, 893-894.	11.2	8

#	Article	IF	Citations
37	Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models. Life Science Alliance, 2021, 4, e202000952.	2.8	4
38	Bispecific antibodies come to the aid of cancer immunotherapy. Molecular Oncology, 2021, 15, 1759-1763.	4.6	3
39	Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. Molecular Therapy, 2016, 24, 1173-1177.	8.2	1
40	Non-Random Selection of Cancer-Causing Mutations in Tissue-Specific Stem Cells Cause Cancer. Journal of Clinical Oncology and Research, 2020, 8, .	0.5	1